メリムスキー教授は、ソラスキー医療センターの軟部組織・骨腫瘍科の責任者であり、胸腺摘出術および肉腫治療において豊富な専門知識を有しています。
ソラック医師は胸腺摘出術を専門としており、ハジェテペ大学がん研究所およびMDアンダーソンがんセンターで広範なトレーニングを受けています。
バリス・トプチュラー医師は神経学を専門とし、運動障害や認知症において豊富な経験を持ち、イスタンブール・フローレンス・ナイチンゲール病院などの権威ある施設で勤務しています。
ヴィオラ・フォックス博士は、認定された学際的がんセンターであるBKZゾーリンゲンの血液学・腫瘍学・緩和ケアクリニックを率いています。
ポンデラス・アカデミック病院の低侵襲およびロボット支援胸腺摘出術の専門医。ドブリトイ医師は、より早い回復のために小さな切開を使用します。
アレムダル医師は胸腺摘出術を専門としており、アクデニズ大学で腫瘍内科の広範なトレーニングを受けています。
ヘスス・ロメロ・インブロダ医師は、キロンサルド・マルベーリャの神経内科医です。欧州神経学会（European Board of Neurology）のフェローであり、王立医学アカデミーの会員でもあります。多発性硬化症の研究と複雑な神経筋疾患を専門としています。また、グラナダ大学で教鞭も執っています。
当医師は著名な神経内科医であり、100件の臨床試験の主任研究員を務めています。多発性硬化症、パーキンソン病、アルツハイマー病、筋萎縮性側索硬化症を専門としています。血漿交換療法や外骨格（エクソスケルトン）などの神経リハビリテーション技術を含む、高度な治療介入を行っています。
主要な大学病院で神経内科部長としてのリーダーシップを発揮してきたキャリアを持ち、医学教授としての認定を受けています。熟練した研究者として、400以上の科学論文を執筆し、そのうち139の国際論文は4,500回以上引用されています。また、カルロス3世健康研究所から資金提供を受けた数多くの研究プロジェクトを主導してきました。
エラ・シマイ・ゼンギン医師は、トルコのトップクラスの医学部で広範な教育を受け、Medicalpoint International Hospitalにて幅広い神経疾患の治療を行っています。
重症筋無力症の専門医 – ウルヴィ・サマザデは、ドクズ・エイリュル大学病院にて複雑な神経筋疾患の研修を修了。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
シュリダール・P.S.医師は放射線治療を専門とし、HCGマナヴァタがんセンターでの胸腺摘出術を含む腫瘍学の広範なトレーニングを受けています。
Shaunak Valame医師は胸腺摘出術を専門とし、標的療法と分子がん研究に重点を置いています。彼は米国臨床腫瘍学会で胃がんに関する研究を発表しました。
Gül Alço教授は、約27年の経験を持つ放射線腫瘍医です。乳がん、肺がん、前立腺がん、消化器がん、婦人科がん、中枢神経系腫瘍、頭頸部がん、軟部組織腫瘍、骨腫瘍の放射線治療を行っています。
専門分野は、適応放射線治療とラジオサージャリー（放射線外科）です。高度な放射線技術を駆使し、患者中心の多職種連携環境において、個別化された科学的根拠に基づくケアを提供しています。
アブドラ・サキン教授（Prof. Dr. Abdullah Sakin）は、腫瘍内科の教授です。肺がん、乳がん、消化器がん、泌尿器がん、婦人科がん、頭頸部がん、悪性黒色腫（メラノーマ）などの固形腫瘍を専門としています。
科学的根拠に基づいた個別化医療を提供しています。治療法には、化学療法、分子標的療法、免疫療法、ホルモン療法、精密腫瘍学（プレシジョン・オンコロジー）が含まれます。200本以上の科学論文を執筆しており、国際的な臨床研究にも積極的に参加しています。これらの活動は、患者中心のがん医療の発展に寄与しています。
50,000件以上の癌手術実績 – ラージ医師は、HCG Manavata Cancer Centreにて乳房および胸部外科腫瘍学を専門としています。
_doctor_2291_年間で10,000件以上の主要手術を執刀 – バンスワル医師は、HCG Manavata Cancer Centreにて、優れた成果を上げる低侵襲がん手術を専門としています。
| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 41年の経験 | 胸腺摘出術および複雑な肉腫症例 | イスラエル屈指の肉腫ユニットを率い、胸腺摘出術における希少な専門知識を持つ。ギュスターヴ・ルッシ研究所にて世界的に著名な肉腫専門医の指導を受けた。 | イスラエル | から $950 | |
| #2 | 20年の経験 | がん症例に対する胸腺摘出術 | MDアンダーソンを含むトップクラスのがん研究所で訓練を受け、複雑ながん手術を専門としています。乳がん、肺がん、消化器がんの専門知識を有しています。 | トルコ | から $100 | |
| #3 | 20年の経験 | 運動障害および認知症 | 運動障害と認知症に重点を置いた神経学の専門家。バーゼル大学を含むトップクラスの施設で研修を受けています。 | トルコ | お問い合わせください | |
| #4 | 14年の経験 | 血液腫瘍疾患 | 個別化治療に重点を置く認定がんセンターを率いる。遺伝学を専門とし、最先端の分子生物学研究に積極的に取り組んでいる。 | ドイツ | お問い合わせください | |
| #5 | 11年の経験 | 低侵襲胸腺摘出術 | 最適な回復のためのロボット支援およびVATS胸腺摘出術の技術に特化。現代の低侵襲アプローチを用いた複雑な縦隔切除の訓練を受けています。 | ルーマニア | お問い合わせください | |
| #6 | 20年の経験 | 重症筋無力症に対する胸腺摘出術 | 重症筋無力症の症例に重点を置いた胸腺摘出術を専門とする。胸部外科の主要センターであるアクデニズ大学で研修を受けた。 | トルコ | お問い合わせください | |
| #7 | 5年の経験 | 重症筋無力症の治療 | 高度な治療法を含む重症筋無力症の治療を専門としています。トルコの主要大学で研修を受け、トップクラスの神経学会に所属しています。 | トルコ | お問い合わせください | |
| #8 | 7年の経験 | 重症筋無力症 | 神経筋疾患の専門家 – IVIG療法および血漿交換療法に精通。国際パーキンソン病・運動障害学会会員。 | トルコ | お問い合わせください | |
| #9 | 30年の経験 | 胸腺摘出術 | 放射線治療を専門とし、胸腺摘出術を含む腫瘍学の広範なトレーニングを受けています。複数の権威ある腫瘍学会の会員です。 | インド | お問い合わせください | |
| #10 | 10年の経験 | 標的療法を伴う胸腺摘出術 | 分子がん研究と標的療法を専門とする。米国臨床腫瘍学会のシンポジウムで発表実績あり。 | インド | お問い合わせください |